Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD99 CAR-T cells
- Development stage
- Unknown
- Lead developer
- The Affiliated Hospital of Xuzhou Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-CD99 CAR-T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target the CD99 antigen (also known as MIC2). CD99 is a cell surface glycoprotein that is highly expressed in several malignancies, including Ewing sarcoma, T-cell acute lymphoblastic leukemia (T-ALL), and certain myeloid leukemias. The therapy involves genetically engineering a patient's T cells to express a CAR that specifically recognizes CD99, enabling the T cells to identify and eliminate CD99-positive tumor cells. This specific program is being evaluated by the Affiliated Hospital of Xuzhou Medical University in China for the treatment of relapsed or refractory CD99-positive lymphoproliferative diseases and other CD99-expressing cancers.
- Other names
- anti-CD99 CAR-Tanti-CD-99 CAR-Tanti-CD 99 CAR-TCD99-targeted CAR-T cellsCD-99-targeted CAR-T cellsCD 99-targeted CAR-T cells
02
Targets
CD99 (CD99 molecule)
Beyond the preview
Go deeper on anti-CD99 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD99 CAR-T cells.